After pharmacotherapy , coverage eligibility was withdrawn from the full coverage group , continuous abstinence between weeks 26 and 52 was 6.6 % ( n = 46 ) and 5.6 % ( n = 38 ) , in the full coverage and no coverage groups , respectively ; OR = 1.19 , 95 % CI 0.76-1 .87 ; p = 0.439 .